Europe

Britain’s AstraZeneca posts revenue boost, with 2.5bn jabs released

Published

3 years ago

February 10, 2022

Sheji Halima

British pharmaceutical company AstraZeneca said on Thursday that its total revenue increased by 41 per cent in 2021, while core earnings per share (EPS) grew by 32 per cent.

The company noted that it had delivered on the promise of broad and equitable access to its COVID-19 vaccine with 2.5 billion doses released for supply around the world.

AstraZeneca is increasing the dividend for shareholders, and said it is confident in long term growth and profitability.

For 2022 fiscal year, the company projects total revenue to increase by a high teens percentage and core EPS to increase by a mid-to-high twenties percentage.

However, reflecting increased confidence in future growth and cash generation, the board plans to increase the annualised dividend by 0.10 dollars to 2.90 dollars.

Meanwhile, the total revenue, excluding the vaccine increased by 26 per cent to 33.44 billion dollars.

Related Topics:

Up Next

Africa vaccine production long term project- CDC

Don't Miss

WHO highlights benefits, dangers of artificial intelligence for older people

Sheji Halima

NEWSVERGE, published by The Verge Communications is an online community of international news portal and social advocates dedicated to bringing you commentaries, features, news reports from a Nigerian-African perspective. A unique organization, founded in the spirit of Article 19 of the Universal Declaration of Human Rights, comprising of ordinary people with an overriding commitment to seeking the truth and publishing it without fear or favour. The Verge Communications is fully registered with the Corporate Affairs Commission of the Federal Republic of Nigeria as a corporate organization.